



P: 8.5818 - Patentlaan
 2280 HV Rijswijk (ZH)
 ☎ +31 70 340 2040
 TX 31651 epo nl
 FAX +31 70 340 3016

Europäisches
 Patentamt

Zweigstelle
 in Den Haag
 Recherchen-
 abteilung

Eu. oan
 Patent Office

Branch at
 The Hague
 Search
 division

Office européen
 des brevets

Département à
 La Haye
 Division de la
 recherche

RECEIVED 23 MAY 2002

09/869122

#11

Geering, Keith Edwin
 REDDIE & GROSE
 16 Theobalds Road
 London WC1X 8PL
 GRANDE BRETAGNE

SYSTEM			
TECHNICAL	YES	DATE:	
EUROPEAN		INITIALS	CHECKED
REGISTERS			
A.B.S.			

Datum/Date
23.05.02

Zeichen/Ref./Réf. KEG/43270	Anmeldung Nr./Application No./Demande n°/Patent Nr./Patent No./Brevet n°. 99961332.6-2123-JP9907236
Anmelder/Applicant/Demandeur/Patentinhaber/Proprietor/Titulaire YAMANOUCI PHARMACEUTICAL CO. LTD.	

COMMUNICATION


The European Patent Office herewith transmits as an enclosure the European search report for the above-mentioned European patent application.

If applicable, copies of the documents cited in the European search report are attached.

Additional set(s) of copies of the documents cited in the European search report is (are) enclosed as well.

REFUND OF THE SEARCH FEE

If applicable under Article 10 Rules relating to fees, a separate communication from the Receiving Section on the refund of the search fee will be sent later.





European Patent
Office

**SUPPLEMENTARY
PARTIAL EUROPEAN SEARCH REPORT**

Application Number

which under Rule 45 of the European Patent Convention shall be considered, for the purposes of subsequent proceedings, as the European search report

EP 99 96 1332

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int.Cl.7)
X	EP 0 647 649 A (YAMANOUCHI PHARMA CO LTD) 12 April 1995 (1995-04-12) * page 2, line 9-14 * * page 5, line 26 - line 29 * * claims 6,7 *	1-6	A61K31/675 A61K45/00 A61P19/08 A61P35/00
Y	* page 2, line 9 - line 14 *	7,8	
Y	KUNZMANN V ET AL: "Pamidronate induces gammadelta T cell expansion in vivo and mediates anti-plasma cell activity in multiple myeloma." BLOOD, vol. 92, no. 10 SUPPL. 1 PART 1-2, 15 November 1998 (1998-11-15), page 279B XP000861909 40th Annual Meeting of the American Society of Hematology; Miami Beach, Florida, USA; December 4-8, 1998 ISSN: 0006-4971 * the whole document *	7,8	
			TECHNICAL FIELDS SEARCHED (Int.Cl.7)
			A61K A61P
The supplementary search report has been based on the last set of claims valid and available at the start of the search.			
INCOMPLETE SEARCH			
The Search Division considers that the present application, or some or all of its claims, does/do not comply with the EPC to such an extent that a meaningful search into the state of the art cannot be carried out, or can only be carried out partially, for the following claims:			
Claims searched completely :			
Claims searched incompletely :			
Claims not searched :			
Reason for the limitation of the search: see sheet C			
Place of search MUNICH		Date of completion of the search 14 May 2002	Examiner Albrecht, S
CATEGORY OF CITED DOCUMENTS			
X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document		T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons & : member of the same patent family, corresponding document	

4

EPO FORM 1503 03.82 (P04C20)



Although claim 7 is directed to a method of treatment of the human/animal body (Article 52(4) EPC), the search has been carried out and based on the alleged effects of the compound.

Claim(s) searched completely:
2,4-8

Claim(s) searched incompletely:
1,3

Reason for the limitation of the search:

Present claims 1 and 3 relate to a product defined by reference to a desirable characteristic or property, namely the suppression of bone resorption accompanying multiple myeloma and inhibition of multiple myeloma.

The claims cover all products having this characteristic or property, whereas the application provides support within the meaning of Article 84 EPC and/or disclosure within the meaning of Article 83 EPC for only a very limited number of such products. In the present case, the claims so lack support, and the application so lacks disclosure, that a meaningful search over the whole of the claimed scope is impossible. Independent of the above reasoning, the claims also lack clarity (Article 84 EPC). An attempt is made to define the product by reference to a result to be achieved. Again, this lack of clarity in the present case is such as to render a meaningful search over the whole of the claimed scope impossible. Consequently, the search has been carried out for those parts of the claims which appear to be clear, supported and disclosed, namely those parts relating to minodronic acid and its salt (claims 2,4-8) and to the bisphosphonate compounds mentioned in the description at page 3.

ANNEX TO THE EUROPEAN SEARCH REPORT
ON EUROPEAN PATENT APPLICATION NO.

EP 99 96 1332

This annex lists the patent family members relating to the patent documents cited in the above-mentioned European search report. The members are as contained in the European Patent Office EDP file on
The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

14-05-2002

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP 0647649 A	12-04-1995	AU 4356693 A	24-01-1994
		DE 69322087 D1	17-12-1998
		DE 69322087 T2	08-04-1999
		DK 647649 T3	26-07-1999
		EP 0647649 A1	12-04-1995
		ES 2124787 T3	16-02-1999
		US 5480875 A	02-01-1996
		AT 173267 T	15-11-1998
		WO 9400462 A1	06-01-1994
		JP 2721434 B2	04-03-1998
